AstraZeneca PLC
NYSE:AZN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
AstraZeneca PLC (AZN) under the Base Case is 170.31 USD per share.
Compared with the current market price of 186.43 USD, the stock appears
Overvalued by 9% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What AstraZeneca Does
AstraZeneca is a global pharmaceutical company that discovers, develops, and sells prescription medicines. Its drugs treat major illnesses such as cancer, heart and kidney disease, respiratory conditions, and rare diseases. The company works with doctors, hospitals, and health systems, and it earns money mainly by selling patented medicines and, in some cases, by licensing or partnering on drug programs.
- Headquarters
- United Kingdom UK
- Employees
- 96 100
- IPO date
- Sep 21, 2007
AstraZeneca has a wide economic moat
Patents and exclusive rights to sell approved medicines prevent rivals from offering cheaper copies of AstraZeneca’s protected treatments. Its range of protected drugs and continuing development of new medicines spread that protection across several diseases rather than relying on a single product.
Read the full moat analysis
Revenue & Expenses Breakdown
AstraZeneca PLC
Earnings Waterfall
AstraZeneca PLC
What is the Intrinsic Value of one AZN stock?
The intrinsic value for AstraZeneca PLC (AZN) under the Base Case is 170.31 USD.
Is AZN stock undervalued or overvalued?
Compared with the current market price of 186.43 USD, the stock appears Overvalued by 9% .
